Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$86.00K$86.00K+19.4% vs Q3 2023 Net Income-$76.69M-$76.69MN/M vs Q3 2023 EPS Diluted-$1.15-$1.15N/M vs Q3 2023 Operating Income-$83,480,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$67,999,000N/M Margins · derivedOperating margin-97069.8%−25925.3 pt vs Q3 2023
Net margin-89173.3%−22978.8 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end